Vanda Pharmaceuticals Reports Q3 2026 Revenue Growth Driven by Fanapt and NEREUS
Vanda Pharmaceuticals (VNDA) reported third-quarter 2026 revenue of $69.8 million, a 24% increase year-over-year, fueled by strong performance from the Fanapt franchise and the initial commercial rollout of NEREUS. The company significantly narrowed its net loss to $22.6 million, compared to a $62.5 million loss in the previous quarter, as operating expenses decreased by 18% following the conclusion of several Phase III clinical activities. Despite revenue growth, Vanda faces headwinds from generic competition affecting HETLIOZ sales and ongoing cash burn concerns. The company maintains a full-year revenue guidance of over $240 million. Looking ahead, investors are monitoring the development of BYSANTI, with top-line results expected in early 2027, and the clinical progress of NEREUS in mitigating GLP-1 related side effects.
Topics: Financial Guidance Net Loss Improvement Product Sales Revenue Growth